Yokoyama J, Shiga K, Saijo S, Matumoto K, Ogawa Y
Dept. of Otolaryngology, Head and Neck Surgery, Miyagi Cancer Center.
Gan To Kagaku Ryoho. 1999 Jun;26(7):967-73.
Eighteen patients with advanced paranasal sinus carcinomas were treated by "two-route" intra-arterial chemotherapy using cis-diamminedichloroplatinum (CDDP) and sodium thiosulfate (STS) to preserve the hard palate and the eye. In these patients, 100 mg/m2 of CDDP was administered weekly through each feeding artery of the tumor superselectively at 5 mg/min. During infusion of CDDP, STS at a two-hundred fold dose of CDDP was injected through a catheter placed in the brachiocephic vein introduced via the subclavian vein. The complete and partial response rates were 14/18 (78%) and 4/18 (22%), respectively. None of the nine patients following operation showed residual tumors histologically. The peak of the mean total plasma platinum concentration was 5.5 micrograms/ml, and this concentration was rapidly reduced to 1.5 micrograms/ml in 5 hours. The peak of the plasma protein unbound platinum was 3.9 micrograms/ml. This concentration rapidly decreased to almost zero within 5 hours after IA infusion. The mean tumor platinum content achieved by superselective IA infusion was as high as 6.0 micrograms/g tumor, and this decreased rapidly to 2.4 micrograms/g tumor on the 5th day after the 1st intra-arterial infusion. All patients were free from chemotoxicity such as renal, hematological dysfunctions, or gastrointestinal symptoms. Each chemotherapy treatment could be done weekly on schedule. All but one patient was alive for 5-40 months. This new method of chemotherapy appears very effective for advanced paranasal sinus carcinomas.
18例晚期鼻窦癌患者接受了使用顺二氨二氯铂(CDDP)和硫代硫酸钠(STS)的“双途径”动脉内化疗,以保留硬腭和眼球。在这些患者中,每周通过肿瘤的各条供血动脉超选择性地以5mg/min的速度给予100mg/m²的CDDP。在输注CDDP期间,通过经锁骨下静脉置入的头臂静脉内的导管注入剂量为CDDP 200倍的STS。完全缓解率和部分缓解率分别为14/18(78%)和4/18(22%)。9例术后患者中无一例组织学检查显示有残留肿瘤。平均总血浆铂浓度峰值为5.5μg/ml,该浓度在5小时内迅速降至1.5μg/ml。血浆蛋白未结合铂的峰值为3.9μg/ml。该浓度在动脉内输注后5小时内迅速降至几乎为零。通过超选择性动脉内输注达到的平均肿瘤铂含量高达6.0μg/g肿瘤,在首次动脉内输注后第5天迅速降至2.4μg/g肿瘤。所有患者均未出现肾、血液系统功能障碍或胃肠道症状等化学毒性。每次化疗均可按计划每周进行。除1例患者外,所有患者存活5至40个月。这种新的化疗方法对晚期鼻窦癌似乎非常有效。